Inhibition of TGF-β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis

Nature Medicine

Volumn 19, Issue 6, 2013, Pages 704-712

  Zhen, Gehua ^a   Wen, Chunyi ^b,c   Jia, Xiaofeng ^d   Li, Yu ^e   Crane, Janet L ^a   Mears, Simon C ^a   Askin, Frederic B ^a   Frassica, Frank J ^a   Chang, Weizhong ^a   Yao, Jie ^b   Carrino, John A ^a   Cosgarea, Andrew ^a   Artemov, Dmitri ^a   Chen, Qianming ^e   Zhao, Zhihe ^e   Zhou, Xuedong ^e   Riley, Lee ^a   Sponseller, Paul ^a   Wan, Mei ^a   Lu, William Weijia ^b,c   Cao, Xu ^a   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY   (China)

^d Johns Hopkins University   (United States)

^e SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR CRUCIATE LIGAMENT; ARTICLE; BONE ATROPHY; CONTROLLED STUDY; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; OSTEOARTHRITIS; OSTEOID; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; BONE AND BONES; CARTILAGE; CELLS, CULTURED; MALE; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; OSTEOARTHRITIS; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, INBRED LEW; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

MUS;

EID: 84880297184     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3143     Document Type: Article

References (53)

1. Hootman, J.M. & Helmick, C.G. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum. 54, 226-229 (2006).
2. van den Berg, W.B. Osteoarthritis year 2010 in review: pathomechanisms. Osteoarthritis Cartilage 19, 338-341 (2011).
3. Berenbaum, F. Osteoarthritis year 2010 in review: pharmacological therapies. Osteoarthritis Cartilage 19, 361-365 (2011).
4. Hawker, G.A., Mian, S., Bednis, K. & Stanaitis, I. Osteoarthritis year 2010 in review: non-pharmacologic therapy. Osteoarthritis Cartilage 19, 366-374 (2011).
5. Saito, T. et al. Transcriptional regulation of endochondral ossification by HIF-2α during skeletal growth and osteoarthritis development. Nat. Med. 16, 678-686 (2010).
6. Yang, S. et al. Hypoxia-inducible factor-2α is a catabolic regulator of osteoarthritic cartilage destruction. Nat. Med. 16, 687-693 (2010).
7. Wang, Q. et al. Identification of a central role for complement in osteoarthritis. Nat. Med. 17, 1674-1679 (2011).
8. Glasson, S.S. et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 434, 644-648 (2005).
9. Neuhold, L.A. et al. Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J. Clin. Invest. 107, 35-44 (2001).
10. Lories, R.J. & Luyten, F.P. The bone-cartilage unit in osteoarthritis. Nat. Rev. Rheumatol. 7, 43-49 (2011).
11. Madry, H., van Dijk, C.N. & Mueller-Gerbl, M. The basic science of the subchondral bone. Knee Surg. Sports Traumatol. Arthrosc. 18, 419-433 (2010).
12. Burr, D.B. & Radin, E.L. Microfractures and microcracks in subchondral bone: are they relevant to osteoarthrosis? Rheum. Dis. Clin. North Am. 29, 675-685 (2003).
13. Stein, V. et al. Pattern of joint damage in persons with knee osteoarthritis and concomitant ACL tears. Rheumatol. Int. 32, 1197-1208 (2012).
14. Amin, S. et al. Complete anterior cruciate ligament tear and the risk for cartilage loss and progression of symptoms in men and women with knee osteoarthritis. Osteoarthritis Cartilage 16, 897-902 (2008).
15. Hill, C.L. et al. Cruciate ligament integrity in osteoarthritis of the knee. Arthritis Rheum. 52, 794-799 (2005).
16. Suri, S. & Walsh, D.A. Osteochondral alterations in osteoarthritis. Bone 51, 204-211 (2012).
17. Hunter, D.J. et al. Increase in bone marrow lesions associated with cartilage loss: a longitudinal magnetic resonance imaging study of knee osteoarthritis. Arthritis Rheum. 54, 1529-1535 (2006).
18. Dreier, R. Hypertrophic differentiation of chondrocytes in osteoarthritis: the developmental aspect of degenerative joint disorders. Arthritis Res. Ther. 12, 216 (2010).
19. Tchetina, E.V. Developmental mechanisms in articular cartilage degradation in osteoarthritis. Arthritis 2011, 683970 (2011).
20. Blaney Davidson, E.N., van der Kraan, P.M. & van den Berg, W.B. TGF-β and osteoarthritis. Osteoarthritis Cartilage 15, 597-604 (2007).
21. Yang, X. et al. TGF-β/Smad3 signals repress chondrocyte hypertrophic differentiation and are required for maintaining articular cartilage. J. Cell Biol. 153, 35-46 (2001).
22. Wu, Q. et al. Induction of an osteoarthritis-like phenotype and degradation of phosphorylated Smad3 by Smurf2 in transgenic mice. Arthritis Rheum. 58, 3132-3144 (2008).
23. Blaney Davidson, E.N. et al. Increase in ALK1/ALK5 ratio as a cause for elevated MMP-13 expression in osteoarthritis in humans and mice. J. Immunol. 182, 7937-7945 (2009).
24. van der Kraan, P.M., Blaney Davidson, E.N., Blom, A. & van den Berg, W.B. TGF-β signaling in chondrocyte terminal differentiation and osteoarthritis: modulation and integration of signaling pathways through receptor-Smads. Osteoarthritis Cartilage 17, 1539-1545 (2009).
25. van der Kraan, P.M., Blaney Davidson, E.N. & van den Berg, W.B. A role for age-related changes in TGFβ signaling in aberrant chondrocyte differentiation and osteoarthritis. Arthritis Res. Ther. 12, 201 (2010).
26. Scharstuhl, A. et al. Inhibition of endogenous TGF-β during experimental osteoarthritis prevents osteophyte formation and impairs cartilage repair. J. Immunol. 169, 507-514 (2002).
27. Scharstuhl, A., Vitters, E.L., van der Kraan, P.M. & van den Berg, W.B. Reduction of osteophyte formation and synovial thickening by adenoviral overexpression of transforming growth factor β/bone morphogenetic protein inhibitors during experimental osteoarthritis. Arthritis Rheum. 48, 3442-3451 (2003).
28. Tang, Y. et al. TGF-β1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 15, 757-765 (2009).
29. Hahn, M., Vogel, M., Pompesius-Kempa, M. & Delling, G. Trabecular bone pattern factor - a new parameter for simple quantification of bone microarchitecture. Bone 13, 327-330 (1992).
30. Pritzker, K.P. et al. Osteoarthritis cartilage histopathology: grading and staging. Osteoarthritis Cartilage 14, 13-29 (2006).
31. Shi, M. et al. Latent TGF-β structure and activation. Nature 474, 343-349 (2011).
32. Whyte, M.P. et al. Camurati-Engelmann disease: unique variant featuring a novel mutation in TGFβ1 encoding transforming growth factor β 1 and a missense change in TNFSF11 encoding RANK ligand. J. Bone Miner. Res. 26, 920-933 (2011).
33. Lotz, M. Osteoarthritis year 2011 in review: biology. Osteoarthritis Cartilage 20, 192-196 (2012).
34. Méndez-Ferrer, S. et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466, 829-834 (2010).
35. Wiese, C. et al. Nestin expression - a property of multi-lineage progenitor cells? Cell Mol. Life Sci. 61, 2510-2522 (2004).
36. Kamekura, S. et al. Osteoarthritis development in novel experimental mouse models induced by knee joint instability. Osteoarthritis Cartilage 13, 632-641 (2005).
37. Goumans, M.J. et al. Balancing the activation state of the endothelium via two distinct TGF-β type I receptors. EMBO J. 21, 1743-1753 (2002).
38. Lorts, A., Schwanekamp, J.A., Baudino, T.A., McNally, E.M. & Molkentin, J.D. Deletion of periostin reduces muscular dystrophy and fibrosis in mice by modulating the transforming growth factor-β pathway. Proc. Natl. Acad. Sci. USA 109, 10978-10983 (2012).
39. Edwards, J.R. et al. Inhibition of TGF-β signaling by 1D11 antibody treatment increases bone mass and quality in vivo. J. Bone Miner. Res. 25, 2419-2426 (2010).
40. Ma, Y., Li, W.Z., Guan, S.X., Lai, X.P. & Chen, D.W. Evaluation of tetrandrine sustained release calcium alginate gel beads in vitro and in vivo. Yakugaku Zasshi 129, 851-854 (2009).
41. Downs, E.C., Robertson, N.E., Riss, T.L. & Plunkett, M.L. Calcium alginate beads as a slow-release system for delivering angiogenic molecules in vivo and in vitro. J. Cell Physiol. 152, 422-429 (1992).
42. Zhang, M. et al. Smad3 prevents β-catenin degradation and facilitates β-catenin nuclear translocation in chondrocytes. J. Biol. Chem. 285, 8703-8710 (2010).
43. Li, T.F. et al. Smad3-deficient chondrocytes have enhanced BMP signaling and accelerated differentiation. J. Bone Miner. Res. 21, 4-16 (2006).
44. Sekiya, I. et al. Human mesenchymal stem cells in synovial fluid increase in the knee with degenerated cartilage and osteoarthritis. J. Orthop. Res. 30, 943-949 (2012).
45. Koyama, N. et al. Pluripotency of mesenchymal cells derived from synovial fluid in patients with temporomandibular joint disorder. Life Sci. 89, 741-747 (2011).
46. Hunter, D.J. et al. Bone marrow lesions from osteoarthritis knees are characterized by sclerotic bone that is less well mineralized. Arthritis Res. Ther. 11, R11 (2009).
47. Cunha, S.I. & Pietras, K. ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood 117, 6999-7006 (2011).
48. Guiducci, S. et al. Bone marrow-derived mesenchymal stem cells from early diffuse systemic sclerosis exhibit a paracrine machinery and stimulate angiogenesis in vitro. Ann. Rheum. Dis. 70, 2011-2021 (2011).
49. Kasper, G. et al. Mesenchymal stem cells regulate angiogenesis according to their mechanical environment. Stem Cells 25, 903-910 (2007).
50. Li, B. & Aspden, R.M. Mechanical and material properties of the subchondral bone plate from the femoral head of patients with osteoarthritis or osteoporosis. Ann. Rheum. Dis. 56, 247-254 (1997).
51. Goldring, S.R. Alterations in periarticular bone and cross talk between subchondral bone and articular cartilage in osteoarthritis. Ther. Adv. Musculoskelet. Dis. 4, 249-258 (2012).
52. Goldring, S.R. Role of bone in osteoarthritis pathogenesis. Med. Clin. North Am. 93, 25-35 (2009).
53. Goldring, M.B. & Goldring, S.R. Osteoarthritis. J. Cell. Physiol. 213, 626-634 (2007).